OVERVIEW

63rd Thomas L. Petty Aspen Lung Conference is organized by University of Colorado - The Division of Pulmonary Sciences and Critical Care Medicine. This onsite medical conference will be held from Sep 20 - 23, 2021 at The Gant, 610 S W End St, Aspen, Colorado, United States of America. This conference also held as Virtual.

Intended Audience:
Local/Regional/National/International Physicians/Clinicians (adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health.

Description:
The 2021 Thomas L. Petty Aspen Lung Conference will integrate basic, translational, and clinical approaches to address the impact of ARDS heterogeneity, with a focus on (1) understanding the presence and therapeutic significance of ARDS mechanistic and phenotypic subtypes, (2) exploring multi-cellular and multi-systemic mechanisms responsible for this heterogeneity, and (3) determining how to best account for disease heterogeneity during clinical trial design and outcome assessment. Heterogeneity within COVID-19 ARDS, as well as between COVID-19 and non-COVID-19 ARDS, will also be discussed.

This conference will provide an international forum bringing together leading basic, translational, and clinical ARDS researchers while welcoming trainees in pulmonology and critical care medicine, with the goal of identifying shared interests that will lead to more productive research and more effective personalized therapies. Finally, the varied scientific themes and therapeutic strategies emerging during the conference will be reconciled in a concluding Conference Summary presented by Dr. Thomas Martin (University of Washington).

Learning Objectives:
The 2021 Aspen Lung Conference has the following learning objectives:
• To discuss the historical rationale for, and current clinical significance of, ARDS phenotypic and genetic heterogeneity. After a focused review of the history of mechanistic ARDS investigations, thought leaders in ARDS heterogeneity will detail the evidence supporting the presence of phenotypic and genetic ARDS patient “endotypes”, inviting audience debate.
• To review and debate emerging mechanistic concepts potentially responsible for ARDS heterogeneity. Via State-of-the-Art lectures by emerging and established experts in the field, we will address critical concepts such as the complexity of epithelial signaling during lung repair, the vascular cross-talk of multisystem organ failure during ARDS, and leukocyte heterogeneity during pulmonary inflammation.
• To integrate concepts of ARDS heterogeneity into clinical trial design. Experts in ARDS trial design and patient-centered outcomes will discuss emerging concepts in patient enrollment, outcome measures, and study design. We will introduce novel “phenomic” approaches, representing big-data opportunities to utilize clinically-collected patient data to provide novel insights into ARDS pathogenesis.

Additional details will be posted as soon as information is available.